Intranet Areál web

Lecture "Non-canonical roles of the Glucocorticoid Receptor in BoneImmunoMetabolism and beyond"

Prof. Jan Tuckermann, University of Ulm, Germany

Osteoporosis and diabetes are common diseases with a high prevalence in the aging population all over the world. Chronic low grade inflammation associated with these conditions impairs insulin sensitivity and has also profound impact on bone quality. Inhibiting inflammatory response in the organism by glucocorticoids decreases inflammation. On the other hand, it has side effects on glucose tolerance and bone homeostasis. Emerging research findings of Prof. Tuckermann provide a new insight in the role of GR signaling in cellular metabolism and how it regulates tissue homeostasis, including bone integrity. These novel non-cannonical actions of GR may represent new therapeutic approaches in the treatment of metabolic and inflammatory bone diseases.


Prof. Jan Tuckermann received his PhD from at the German Cancer Research Center (DKFZ), Heidelberg, University of Karlsruhe, Karlsruhe, Germany and was trained in molecular and cellular biology (DKFZ, Heidelberg) and bone biology (FLI, Jena). Jan is a professor and a director of the Institute of Comparative Molecular Endocrinology, Ulm University, Ulm. He has an excellent publication track record and he is a a well-recognized expert in the field of bone physiology and the holder of several prestigues grants and awards. His research is focused on the glucocorticoid receptor signaling in bone immunometabolism, especially investigating the cross-talk of immune and stromal cells during osteoarthritis and diabetes and how resolution of inflammation can be fine tuned to alleviate disease and to allow repair of tissue integrity. Studying the GR signaling pathway opens up opportunities for new therapeutic concepts to tackle the metabolic and inflammatory diseases associated with the aging process. 

IPHYS contact person: Michaela Tencerova,

Lecture is supported by the project CarDia - National Institute for Research of Metabolic and Cardiovascular Diseases (Programme EXCELES, ID Project No. LX22NPO5104) – Funded by the European Union – Next Generation EU.